<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04384484</url>
  </required_header>
  <id_info>
    <org_study_id>ADCT-402-311</org_study_id>
    <secondary_id>2020-000241-14</secondary_id>
    <nct_id>NCT04384484</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma</brief_title>
  <acronym>LOTIS 5</acronym>
  <official_title>A Phase 3 Randomized Study of Loncastuximab Tesirine Combined With Rituximab Versus Immunochemotherapy in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ADC Therapeutics S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ADC Therapeutics S.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of loncastuximab tesirine (ADCT-402)&#xD;
      combined with rituximab compared to standard immunochemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2028</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Up to 4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rate (CRR)</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experience At Least One Treatment-Emergent Adverse Event (TEAE)</measure>
    <time_frame>Day 1 up to a maximum of Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experience At Least One Serious Adverse Event (SAE)</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experience a Clinically Significant Change From Baseline in Clinical Laboratory Results</measure>
    <time_frame>Day 1 up to a maximum of Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experience a Clinically Significant Change From Baseline in Vital Sign Measurements</measure>
    <time_frame>Day 1 up to a maximum of Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experience a Clinically Significant Change From Baseline in Physical Examinations</measure>
    <time_frame>Day 1 up to a maximum of Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experience a Clinically Significant Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status</measure>
    <time_frame>Day 1 up to a maximum of Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experience a Clinically Significant Change From Baseline in Electrocardiogram (ECG) Results</measure>
    <time_frame>Day 1 up to a maximum of Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Concentration of Loncastuximab Tesirine at the End of Infusion</measure>
    <time_frame>Day 1 of Cycles 1 through 6 (each cycle is 3 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Concentration of Loncastuximab Tesirine Before Infusion</measure>
    <time_frame>Day 1 of Cycles 2 through 6 (each cycle is 3 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anti-Drug Antibody (ADA) Titers to Loncastuximab Tesirine</measure>
    <time_frame>Day 1 up to a maximum of Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change from Baseline in Health-Related Quality of Life (HRQoL) as Measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire -Core 30 (EORTC QLQ-C30)</measure>
    <time_frame>Baseline up to a maximum of Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change from Baseline in Health-Related Quality of Life (HRQoL) as Measured by the Lymphoma Subscale of Functional Assessment of Cancer Therapy- Lymphoma (LymS of FACT-Lym)</measure>
    <time_frame>Baseline up to a maximum of Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change from Baseline in Health-Related Quality of Life (HRQoL) as Measured by GP5 Item of the Functional Assessment of Cancer Therapy- Lymphoma (FACT-Lym)</measure>
    <time_frame>Baseline up to a maximum of Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Change from Baseline in Health-Related Quality of Life (HRQoL) as Measured by EuroQol-5 Dimensions-5 Levels (EQ-5D-5L)</measure>
    <time_frame>Baseline to up to 4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Relapsed Diffuse Large B-Cell Lymphoma</condition>
  <condition>Refractory Diffuse Large B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Part 1: Loncastuximab Tesirine + Rituximab (Lonca-R)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1 consists of a non-randomized safety run-in period evaluating the study drug for the first 20 participants.&#xD;
Participants will receive Lonca-R on Day 1 of each cycle for up to 8 cycles, where 1 cycle is 3 weeks. Lonca-R will be administered via an intravenous infusion of loncastuximab tesirine 150 µg/kg + rituximab 375 mg/m^2 Q3W for 2 cycles, then loncastuximab tesirine 75 µg/kg + rituximab 375 mg/m^2 Q3W for up to 6 additional cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Loncastuximab Tesirine + Rituximab (Lonca-R)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized participants will receive Lonca-R on Day 1 of each cycle for up to 8 cycles, where 1 cycle is 3 weeks. Lonca-R will be administered via an intravenous infusion of loncastuximab tesirine 150 µg/kg + rituximab 375 mg/m^2 every Q3W for 2 cycles, then loncastuximab tesirine 75 µg/kg + rituximab 375 mg/m^2 Q3W for up to 6 additional cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Standard Immunochemotherapy (R-GemOx)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomized participants will receive R-GemOx consisting of rituximab, gemcitabine and oxaliplatin as a standard immunochemotherapy treatment on Day 1 of each cycle for up to 8 cycles, where 1 Cycle is 2 weeks. R-GemOx will be administered via an intravenous infusion of rituximab 375 mg/m^2 + gemcitabine 1000 mg/m^2 + oxaliplatin 100 mg/m^2 every 2 weeks (Q2W) for up to 8 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loncastuximab Tesirine</intervention_name>
    <description>Intravenous Infusion</description>
    <arm_group_label>Part 1: Loncastuximab Tesirine + Rituximab (Lonca-R)</arm_group_label>
    <arm_group_label>Part 2: Loncastuximab Tesirine + Rituximab (Lonca-R)</arm_group_label>
    <other_name>Zynlonta</other_name>
    <other_name>ADCT-402</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Intravenous Infusion</description>
    <arm_group_label>Part 1: Loncastuximab Tesirine + Rituximab (Lonca-R)</arm_group_label>
    <arm_group_label>Part 2: Loncastuximab Tesirine + Rituximab (Lonca-R)</arm_group_label>
    <arm_group_label>Part 2: Standard Immunochemotherapy (R-GemOx)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Intravenous Infusion</description>
    <arm_group_label>Part 2: Standard Immunochemotherapy (R-GemOx)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Intravenous Infusion</description>
    <arm_group_label>Part 2: Standard Immunochemotherapy (R-GemOx)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female participant aged 18 years or older&#xD;
&#xD;
          -  Pathologic diagnosis of DLBCL, as defined by the 2016 World Health Organization&#xD;
             classification (including participants with DLBCL transformed from indolent lymphoma),&#xD;
             or high-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements&#xD;
&#xD;
          -  Relapsed (disease that has recurred following a response) or refractory (disease that&#xD;
             failed to respond to prior therapy) disease following at least one multi-agent&#xD;
             systemic treatment regimen&#xD;
&#xD;
          -  Not considered by the investigator to be a candidate for stem cell transplantation&#xD;
             based on performance status, advanced age, and/or significant medical comorbidities&#xD;
             such as organ dysfunction&#xD;
&#xD;
          -  Participants who have received previous CD19-directed therapy must have a biopsy which&#xD;
             shows CD19 expression after completion of the CD19-directed therapy&#xD;
&#xD;
          -  Measurable disease as defined by the 2014 Lugano Classification as assessed by&#xD;
             positron-emission tomography (PET)- computed tomography (CT) or by CT or magnetic&#xD;
             resonance imaging (MRI) if tumor is not fluorodeoxyglucose (FDG)-avid on screening&#xD;
             PET-CT&#xD;
&#xD;
          -  Availability of formalin-fixed paraffin-embedded (FFPE) tumor tissue block (or minimum&#xD;
             10 freshly cut unstained slides if block is not available) Note: Any biopsy since&#xD;
             initial diagnosis is acceptable, but if several samples are available, the most recent&#xD;
             sample is preferred&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Adequate organ function as defined by screening laboratory values within the following&#xD;
             parameters:&#xD;
&#xD;
               1. Absolute neutrophil count ≥1000/μL (off growth factors for at least 72 hours)&#xD;
&#xD;
               2. Platelet count ≥75000/μL without transfusion within the past 2 weeks&#xD;
&#xD;
               3. ALT, AST, and GGT ≤2.5 × the upper limit of normal (ULN)&#xD;
&#xD;
               4. Total bilirubin ≤1.5 × ULN (participants with known Gilbert's syndrome may have a&#xD;
                  total bilirubin up to ≤3 × ULN)&#xD;
&#xD;
               5. Calculated creatinine clearance ≥30 mL/min by the Cockcroft and Gault equation&#xD;
&#xD;
        Note: A laboratory assessment may be repeated a maximum of two times during the Screening&#xD;
        period to confirm eligibility.&#xD;
&#xD;
          -  Negative beta-human chorionic gonadotropin (β-hCG) pregnancy test within 7 days prior&#xD;
             to start of study drug (Cycle 1 Day 1) for women of childbearing potential&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must agree to use a highly effective method of&#xD;
             contraception from the time of giving informed consent until at least 9 months after&#xD;
             the last dose of loncastuximab tesirine. Men with female partners who are of&#xD;
             childbearing potential must agree that they will use a highly effective method of&#xD;
             contraception from the time of giving informed consent until at least 6 months after&#xD;
             the participant receives his last dose of loncastuximab tesirine.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with loncastuximab tesirine&#xD;
&#xD;
          -  Previous treatment with R-GemOx&#xD;
&#xD;
          -  Known history of hypersensitivity to or positive serum human ADA to a CD19 antibody&#xD;
&#xD;
          -  Pathologic diagnosis of Burkitt lymphoma&#xD;
&#xD;
          -  Active second primary malignancy other than non-melanoma skin cancers, non-metastatic&#xD;
             prostate cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the&#xD;
             breast, or other malignancy that the Sponsor's medical monitor and Investigator agree&#xD;
             and document should not be exclusionary&#xD;
&#xD;
          -  Autologous transplant within 30 days prior to start of study drug (Cycle 1 Day 1)&#xD;
&#xD;
          -  Allogeneic transplant within 60 days prior to start of study drug (Cycle 1 Day 1)&#xD;
&#xD;
          -  Active graft-versus-host disease&#xD;
&#xD;
          -  Post-transplantation lymphoproliferative disorders&#xD;
&#xD;
          -  Active autoimmune disease, including motor neuropathy considered of autoimmune origin&#xD;
             and other central nervous system (CNS) autoimmune disease&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) seropositive with any of the following:&#xD;
&#xD;
               1. CD4+ T-cell (CD4+) counts &lt;350 cells/μL&#xD;
&#xD;
               2. Acquired immunodeficiency syndrome-defining opportunistic infection within 12&#xD;
                  months prior to screening&#xD;
&#xD;
               3. Not on anti-retroviral therapy, or on anti-retroviral therapy for &lt;4 weeks at the&#xD;
                  time of screening&#xD;
&#xD;
               4. HIV viral load ≥400 copies/mL&#xD;
&#xD;
          -  Serologic evidence of chronic hepatitis B virus (HBV) infection and unable or&#xD;
             unwilling to receive standard prophylactic antiviral therapy or with detectable HBV&#xD;
             viral load&#xD;
&#xD;
          -  Serologic evidence of hepatitis C virus (HCV) infection without completion of curative&#xD;
             treatment or with detectable HCV viral load&#xD;
&#xD;
          -  History of Stevens-Johnson syndrome or toxic epidermal necrolysis&#xD;
&#xD;
          -  Lymphoma with active CNS involvement, including leptomeningeal disease&#xD;
&#xD;
          -  Clinically significant third space fluid accumulation (i.e., ascites requiring&#xD;
             drainage or pleural effusion that is either requiring drainage or associated with&#xD;
             shortness of breath)&#xD;
&#xD;
          -  Breastfeeding or pregnant&#xD;
&#xD;
          -  Uncontrolled hypertension (blood pressure ≥160/100 mm Hg repeatedly), unstable angina,&#xD;
             congestive heart failure (greater than New York Heart Association class II),&#xD;
             electrocardiographic evidence of acute ischemia, coronary angioplasty or myocardial&#xD;
             infarction within 6 months prior to screening, uncontrolled atrial or ventricular&#xD;
             cardiac arrhythmia, poorly controlled diabetes, severe chronic pulmonary disease, or&#xD;
             other serious medical condition which is likely to significantly impair the&#xD;
             participant's ability to tolerate the study treatment&#xD;
&#xD;
          -  Major surgery, radiotherapy, chemotherapy or other antineoplastic therapy within 14&#xD;
             days prior to start of study drug (Cycle 1 Day 1), except shorter if approved by the&#xD;
             Sponsor&#xD;
&#xD;
          -  Use of any other experimental medication within 14 days or 5 half-lives prior to start&#xD;
             of study drug (Cycle 1 Day 1)&#xD;
&#xD;
          -  Received live vaccine within 4 weeks of Cycle 1 Day 1&#xD;
&#xD;
          -  Failure to recover to ≤Grade 1 (Common Terminology Criteria for Adverse Events [CTCAE]&#xD;
             version 5.0) from acute non-hematologic toxicity (except alopecia) due to previous&#xD;
             therapy prior to screening&#xD;
&#xD;
          -  Congenital long QT syndrome or a corrected QTcF interval of ≥480 ms at screening&#xD;
             (unless secondary to pacemaker or bundle branch block)&#xD;
&#xD;
          -  Any other significant medical illness, abnormality, or condition that would, in the&#xD;
             Investigator's judgment, make the participant inappropriate for study participation or&#xD;
             put the participant at risk&#xD;
&#xD;
          -  Known history of hypersensitivity to oxaliplatin or any of its excipients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>ADC Therapeutics</last_name>
    <phone>954-903-7994</phone>
    <email>clinical.trials@adctherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Chung</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Redlands Community Hospital</name>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <zip>92373</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Ramos</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Oncology Institute of Hope and Innovation</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsten Bettino</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miami Cancer Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuliya Linhares</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Maly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikki M Glynn-Cunningham</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada - Henderson</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Wu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hollings Cancer Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HCC Clinical Trials Office</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Gainesville</city>
        <state>Virginia</state>
        <zip>20155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Friedman</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin Cancer Center Clinical Trials Office</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehdi Hamadani</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis Sint-Jan Brugge-Oostende - Campus Sint-Jan</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvia Snauwaert</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Universite Catholique de Louvain</name>
      <address>
        <city>Namur</city>
        <zip>B-5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien Depaus</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis Delta - Campus Rumbeke</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dries Deeren</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpitale Pomorskie Spółka Z Ograniczoną Odpowiedzialnością</name>
      <address>
        <city>Gdynia</city>
        <zip>81-519</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wanda Knopinska-Posluszny</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pratia Onkologia Katowice</name>
      <address>
        <city>Katowice</city>
        <zip>40-519</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Grosicki</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Wojewódzki w Opolu</name>
      <address>
        <city>Opole</city>
        <zip>45-061</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dariusz Woszczyk</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pratia Poznań</name>
      <address>
        <city>Skorzewo</city>
        <zip>60-185</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michał Kwaitek</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar - Parc de Salut Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Salar Silvestre</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet)</name>
      <address>
        <city>Barcelona</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Maria Gonzalez Barca</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Juan Miguel Bergua Burgues</name>
      <address>
        <city>Cáceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Miguel Bergua Burgues</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Javier Lopez Jimenez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raul Mascunano</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tycho Baumann</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Angel Canales Albendea</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Gonzalez de Villambrosia</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fatima De La Cruz Vicente</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico della Svizzera Italiana</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anastasios Stathis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Radford</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 8, 2020</study_first_submitted>
  <study_first_submitted_qc>May 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Loncastuximab Tesirine</keyword>
  <keyword>Refractory Diffuse Large B-Cell Lymphoma</keyword>
  <keyword>Relapsed Diffuse Large B-Cell Lymphoma</keyword>
  <keyword>Diffuse Large B-Cell Lymphoma</keyword>
  <keyword>Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Loncastuximab tesirine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

